SEARCH

SEARCH BY CITATION

References

  • 1
    Marrett LD, Chiarelli AM, Nishri ED, Theis B. Cervical cancer in Ontario 1971–1996. Toronto: Cancer Care Ontario, 1999.
  • 2
    Vizcaino AP, Moreno V, Bosch FX, Munoz N, Barros-Dios XM, Borras J, Parkin DM. International trends in incidence of cervical cancer. II. Squamous-cell carcinoma. Int J Cancer 2000; 86: 42935.
  • 3
    Smith HO, Tiffany MF, Qualls CR, Key CF. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States—a 24-year population-based study. Gynecol Oncol 2000; 78: 97105.
  • 4
    Sasieni P, Adams J. Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England. Lancet 2001; 357: 149093.
  • 5
    Chan PG, Sung HY, Sawaya GF. Changes in cervical cancer incidence after three decades of screening US women less than 30 years old. Obstet Gynecol 2003; 102: 76573.
  • 6
    Singh GK, Miller BA, Hankey BF, Edwards BK. Persistent area socioeconomic disparities in U.S. incidence of cervical cancer, mortality, stage, and survival, 1975–2000. Cancer 2004; 101: 10517.
  • 7
    Peto J, Gilham C, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004; 364: 24956.
  • 8
    Wang SS, Sherman ME, Hildesheim A, Lacey JV, Devesa S. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976–2000. Cancer 2004; 100: 103544.
  • 9
    Bray F, Loos AH, McCarron P, Weiderpass E, Arbyn M, Moller H, Hakama M, Parkin M. Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomarkers Prev 2005; 14: 67786.
  • 10
    Nieminen P, Kallio M, Hakama M. The effect of mass screening on incidence and mortality of squamous and adenocarcinoma of cervix uteri. Obstet Gynecol 1995; 85: 101721.
  • 11
    Nieminen P, Kallio M, Anttila A, Hakama M. Organised vs. spontaneous PAP-smear screening for cervical cancer: a case-control study. Int J Cancer 1999; 83: 558.
  • 12
    International Agency for Research on Cancer.IARC handbooks of cancer prevention, vol. 10: Cervix cancer screening. Lyon: IARC Press, 2005.
  • 13
    Vizcaino AP, Moreno V, Bosch FX, Munoz N, Barros-Dios XM, Borras J, Parkin DM. International trends in the incidence of cervical cancer. I. Adenocarcinoma and adenosquamous cell carcinomas. Int J Cancer 1998; 75: 53645.
  • 14
    Armstrong B, Holman D. Increasing mortality from cancer of the cervix in young Australian women. Med J Aust 1981; 1: 4602.
  • 15
    Zheng T, Holford TR, Ma Z, Chen Y, Liu W, Ward BA, Boyle P. The continuing increase in adenocarcinoma of the uterine cervix birth cohort phenomenon. Int J Epidemiol 1996; 25: 2528.
  • 16
    Bergstrom R, Sparen P, Adami H-O. Trends in cancer of the cervix uteri in Sweden following cytological screening. Br J Cancer 1999; 81: 15966.
  • 17
    Alfsen GC, Thoresen SO, Kristensen GB, Skovlund E, Abeler VM. Histopathologic subtyping of cervical adenocarcinoma reveals increasing incidence rates of endometrioid tumors in all age groups. Cancer 2000; 69: 12919.
  • 18
    Liu S, Semenciw R, Probert A, Mao Y. Cervical cancer in Canada: changing patterns in incidence and mortality. Int J Gynecol Cancer 2001; 11: 2431.
  • 19
    Renshaw AA, Mody DR, Lozano RL, Volk EE, Walsh MK, Davey DD, Birdsong GG. Detection of adenocarcinoma in situ of the cervix in Papanicolaou tests: comparison of diagnostic accuracy with other high-grade lesions. Arch Pathol Lab Med 2004; 128: 1537.
  • 20
    Romero AA, Key CR, Smith HO. Changing trends in adenocarcinoma and squamous cell carcinoma by age, race and stage: a 25-year population-based study. Gynecol Oncol 2001; 80: 295296.
  • 21
    Mitchell H, Hocking J, Saville M. Improvement in protection against adenocarcinoma of the cervix resulting from participation in cervical screening. Cancer Cytopathol 2003; 99: 33641.
  • 22
    Kinney W, Sawaya GF, Sung HY, Kearney KA, Miller M, Hiatt R. Stage at diagnosis and mortality in patients with adenocarcinoma and adenosquamous carcinoma of the uterine cervix diagnosed as a consequence of cytologic screening. Acta Cytol 2003; 47: 16771.
  • 23
    Bulk S, Visser O, Rozendaal L, Veerheijen RH, Meijer CJ. Incidence and survival rate of women with cervical cancer in the Greater Amsterdam area. Br J Cancer 2003; 89: 8349.
  • 24
    Andersson S, Larson B, Hjerpe A, Silfversward C, Sallstrom J, Wilander E, Rylander E. Adenocarcinoma of the uterine cervix: the presence of human papillomavirus and the method of detection. Acta Obstet Gynecol Scand 2003; 82: 9605.
  • 25
    Mitchell H, Medley G, Gordon J, Giles G. Cervical cytology reported as negative and risks of adenocarcinoma of the cervix: no strong evidence of benefit. Br J Cancer 1995; 71: 8947.
  • 26
    World Health Organization. International classification of diseases—ninth revision, Geneva: World Health Organization, 1977.
  • 27
    Holowaty EJ, Marrett LD, Fehringer G. Cancer incidence in Ontario: trends and regional variations in the 1980s. Toronto: The Ontario Cancer Treatment and Research Foundation, 1995.
  • 28
    Marrett LD, Nishri ED, Swift MB, et al.Geographic distribution of cancer in Ontario, vol. 2: Atlas of cancer incidence, 1980–1991. Toronto: The Ontario Cancer Treatment and Research Foundation, 1995.
  • 29
    McLaughlin JR, Sloan MR, Janovjak DP. Cancer survival in Ontario. Toronto: The Ontario Cancer Treatment and Research Foundation, 1995.
  • 30
    Holowaty P. The natural history of cervical dysplasia. Dissertation. Toronto: University of Toronto, 1996.
  • 31
    World Health Organization. Manual of the international classification of diseases for oncology, 1st edn. Geneva: World Health Organization, 1976.
  • 32
    PercyC, Van HoltenV, MuirC, eds. International classification of diseases for oncology, 2nd edn. Geneva: World Health Organization, 1990.
  • 33
    ParkinDM, ShanmugaratnamK, SobinL, et al., eds. Histological groups for comparative studies. Lyon, France: International Agency for Research on Cancer. 1998. IARC Technical Report No. 31.
  • 34
    Platz CE, Benda JA. Female genital tract cancer. Cancer 1995; 75: 27094.
  • 35
    Berg JW. Morphologic classification of human cancer. In: SchottenfeldD, FraumeniJF,Jr, eds. Cancer epidemiology and prevention. New York: Oxford University Press, 1996. 2844.
  • 36
    National Cancer Institute. Surveillance research program. SEER, Stat software, version 6.1.4. Bethesda, MD: National Cancer Institute, 2005.
  • 37
    Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000; 19: 33551 (correction: 2001;20:655).
  • 38
    Statistics Canada. Canadian community health survey (CCHS) 2003 (Cycle 2.1), share file. Ottawa: Statistics Canada, Health Statistics Division, 2005.
  • 39
    Marrett LD, Innes M, Howlett RI, Cotterchio M. Cancer Care Ontario. Insight on Cancer: News and Information on Cervical Cancer. Toronto: Canadian Cancer Society (Ontario Division), 2005.
  • 40
    Schoolland M, Allpress S, Sterrett GF. Adenocarcinoma of the cervix. Cancer Cytopathol 2002; 96: 513.
  • 41
    Buntinx F, Brouwers M. Relation between sampling device and detection of abnormality in randomised and quasi-randomised studies. BMJ 1996; 313: 128590.
  • 42
    Martin-Hirsch P, Jarvis G, Kitchener H, Lilford R. Collection devices for obtaining cervical cytology samples. Cochrane Database Syst Rev 2000. CD001036.
  • 43
    Madeleine MM, Daling JR, Schwartz SM, Shera K, McKnight B, Carter JJ, Wipf GC, Critchlow CW, McDougall JK, Porter P, Galloway DA. Human papillomavirus and long-term oral contraceptive use increase the risk of adenocarcinoma in situ of the cervix. Cancer Epidemiol Biomarkers Prev 2001; 10: 1717.
  • 44
    Thompson DW. Adequate “Pap” smears. Laboratory Proficiency Testing Program, Toronto, Ontario, Canada. Quality Management Program, Laboratory Services, 1989.
  • 45
    Chakrabarti S, Guijon FB, Paraskevas M. Brush vs. spatula for cervical smears: histologic correlation with concurrent biopsies. Acta Cytol 1994; 38: 31518.
  • 46
    Cytology, Pattern of Practice Survey Y-92. Laboratory Proficiency Testing Program, Toronto, Ontario, Canada: Quality Management Program, Laboratory Services, 1992.
  • 47
    Cytobase Reports, INSCYTE Corporation. Available at www.inscyte.org/publications/reports.html. (Accessed 1 November 2005).
  • 48
    Lacey JV,Jr, Brinton LA, Abbas FM, Barnes WA, Gravitt PE, Greenberg MD, Greene SM, Hadjimichael OC, McGowan L, Mortel R, Schwartz PE, Silverberg SG et al. Oral contraceptives as risk factors for cervical adenocarcinomas and squamous cell carcinomas. Cancer Epidemiol Biomarkers Prev 1999; 8: 107985.
  • 49
    Statistics Canada. National Population Health Survey (NPHS) 1994/1995, public use microdata file. Ottawa: Statistics Canada, Health Statistics Division, 1995.
  • 50
    Statistics Canada. National Population Health Survey (NPHS) 1996/1997, public use microdata file. Ottawa: Statistics Canada, Health Statistics Division, 1998.
  • 51
    Statistics Canada. National Population Health Survey (NPHS) 1998/1999, public use microdata file. Ottawa: Statistics Canada, Health Statistics Division, 2000.
  • 52
    Martin K, Wu Z. Contraceptive use in Canada: 1984–1995. Fam Plann Perspect 2000; 32: 6573.
  • 53
    Zhang J, Ugnat AM, Clarke K, et al. Ovarian cancer histology-specific incidence trends in Canada 1969–1993: age-period-cohort analyses. Br J Cancer 1999; 81: 1528.
  • 54
    Statistics Canada. Canadian community health survey, Cycle 1.1, 2000–2001, Ottawa, 2002.
  • 55
    Ozkan F, Ramzy I, Mody DR. Glandular lesions of the cervix on thin-layer Pap tests. Validity of cytologic criteria used in identifying significant lesions. Acta Cytol 2004; 48: 3729.
  • 56
    Rowe LR, Marshall CJ, Bentz JS. One hundred percent thorough quality control rescreening of liquid-based monolayers in cervicovaginal cytopathology. Cancer 2002; 96: 3259.
  • 57
    Uvar DS, Eltabbakh GH, Mount SL. Positive predictive value of liquid-based and conventional cervical Papanicolaou smears reported as malignant. Gynecol Oncol 2003; 89: 22732.
  • 58
    Renshaw AA, Young NA, Birdsong GG, Styer PE, Davey DD, Mody DR, Colgan TJ. Comparison of performance of conventional and ThinPrep gynecologic preparations in the College of American Pathologists Gynecologic Cytology Program. Arch Pathol Lab Med 2004; 128: 1722.